welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Molecular Analysis of Patients With Neuromuscular Disease
study id #: NCT00390104
condition: Limb-girdle Muscular Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
The purpose of this study is to identify genes and proteins responsible for nerve and muscle disorders by studying genetic material from individuals with neuromuscular disease, as well as their family members. We are interested in recruiting many types of neuromuscular disease including; Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and limb-girdle muscle dystrophy (LGMD). There are still many patients diagnosed with muscular dystrophy but have no causative gene implicated in their disease. Using molecular genetics to unravel the biochemical basis of these neuromuscular disorders should lead to more accurate diagnosis of these disorders and should lead to potential therapies.
mechanism of action: No pharmaceutical intervention
last updated: March 01, 2020
start date: January 2002
estimated completion: December 31, 2025
phase of development: N/A
size / enrollment: 1000
We are looking to discover new disease genes responsible for the neuromuscular diseases found in our participants and their families. Our research lab has a long history of identifying novel genes responsible for various forms of neuromuscular disease including; DMD gene, the many of the sarcoglycans, obscurin, and filamin. Each discovery has resulted in advances in our ability to develop diagnostic tests which benefit patients and their families by providing accurate diagnosis, presymptomatic and/or prenatal testing. Genotype-phenotype correlation studies have increased our understanding of the natural history of these rare disorders benefiting patients through better prognostic determinations by clinicians. Biochemical and pathological analysis of muscle biopsies in patients with known and unknown types of neuromuscular disease has led to new insights into disease pathophysiology, which we hope will aid in finding new treatments.
• Eligible Sexes: all
• having a clinical and/or pathological diagnosis of a muscular dystrophy
• being the first degree relative of someone with such a diagnosis
• having had a muscle biopsy if diagnosed with a neuromuscular disease
• willingness to provide a skin biopsy for research only
• not having such a diagnosis and not being related to such an individual
• not wishing to participate
• being incapable of giving consent and not having a legal guardian willing or able to do so
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyThe study is to demonstrate non-inferior...
University of Minnesota Clinical Trials May Offer Hope for Local Boys With Duchenne Muscular DystrophyA rare genetic disease called Duchenne M...
Duchenne UK: DMD Patient and Caregiver Survey Resultshttps://www.youtube.com/watch?v=d2EpSB8R...
Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular DystrophyRecent increases in the number and bread...
Tadalafil and Sildenafil for Duchenne Muscular DystrophyThis study, supported by Parent Project ...
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
Dystrophin 101 Webinarhttps://www.youtube.com/watch?v=3VFIXq_h...
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...